Jul. 8 at 12:05 PM
$DRMA is showing all the signs of an early breakout setup with a clean catalyst. Today’s PR confirmed a granted Australian patent for its botulinum toxin therapy, adding to Dermata’s global IP strength after its April Phase 3 trial win. Level 2 shows large bids under 0.74 and a key wall at 0.82, with sweeps hitting at 0.7301–0.7401. No active dilution filings since March, and the chart shows a full EMA/VWAP stack with MACD flipping bullish. Keeping an eye out for volume through 0.84 which could send this to 1.00 fast
Targets: 0.91 / 1.03 / 1.18
Stop: 0.69
